Eye Care

Despite demonstrating numerous benefits, semaglutide has also been linked to an increased incidence of diabetic retinopathy, which was initially reported in the SUSTAIN-6 trial.

Blink Tears Lubricating Eye Drops maximizes hydration and restores tears’ natural salt balance.

Lotemax treats post-operative inflammation and pain following ocular surgery.

AzaSite is indicated for the treatment of bacterial conjunctivitis caused by CDC coryneform group G, Haemophilus influenzae, Staphylococcus aureus, Streptococcus mitis group, and Streptococcus pneumoniae.

Farsightedness usually is present at birth and tends to run in families.

Aflibercept is indicated for the treatment of patients with neovascular (wet) age-related macular degeneration, macular edema following retinal vein occlusion, diabetic macular edema, and diabetic retinopathy.

According to a press release from AbbVie, Vuity is the first and only FDA-approved eye drop to treat this condition, which affects nearly half of the US adult population.

According to the investigators, Susvimo is the first and only FDA-approved treatment for wet AMD that offers as few as 2 treatments per year.

Tafluprost acid, a prostaglandin analog, is a selective FP prostanoid receptor agonist that is believed to reduce intraocular pressure by increasing uveoscleral outflow.

As the first nasal spray for dry eye disease, varenicline solution nasal spray could be especially helpful for patients who have difficulty administering eye drops.

According to GenSight, GS030 combines AAV2-based gene therapy with optogenetics to treat RP.

According to Ocular Therapeutix, Dextenza is now the first FDA-approved, physician-administered intracanalicular insert capable of delivering a preservative-free drug for the treatment of ocular itching associated with allergic conjunctivitis with a single administration for up to 30 days.

Doctors and pharmacists discuss OTC and prescription treatment options and use during webcast.

An anti-vascular endothelial growth factor therapy, ranibizumab prevents vision loss in patients with retinal vascular disorders, which can cause irreversible blindness or visual impairments in adults.

The research team analyzed the associations between maternal diabetes before or during pregnancy and the risk of high refractive error (RE), which are conditions in which there is a failure of the eye to properly focus images on the retina.

According to the investigators, both trials demonstrated an overall well-tolerated safety profile for brolucizumab.

Top-line data from the NORSE TWO trial demonstrated that the treatment met the primary and key secondary endpoint for efficacy with clinically impactful change observed for treated patients.

Investigators observed improvements in inflammation of the cornea and ocular itching among patients receiving Verkazia in both trials.

Topline results from the phase 2/3 XIRIUS study of cotoretigene toliparvovec (BIIB112), a gene therapy being investigated as a one-time therapy for patients with X-linked retinitis pigmentosa (XLRP), found that the study did not meet its primary endpoint of demonstrating a statistically significant improvement in the proportion of treated study eyes.

Case studies include recommendations for eye pain and allergy relief.

Currently, genetic counselors apply their molecular and clinical expertise in diverse roles, many delivered via telehealth.

Patients with this severe condition seem to experience significant differences in quality of life despite having similar visual fields

Four case studies about skin and eye health.

As the nerve exits the eye, the heightened pressure applies mechanical strain to the optic nerve, causing vision loss and potential blindness.

Once accredited for use, the new test will improve doctors’ ability to predict and prevent vision loss from glaucoma.

Over-the-counter products featured in the May 2020 issue.

Pharmacists are in a prime position to convey preventive and treatment options for eyelid inflammation.

In the United States, more than 16 million Americans have DES and that number is expected to increase.

The FDA has approved olopatadine hydrochloride ophthalmic 0.1% and 0.2% solution for sale as an OTC medication in the United States.

Using metformin for type 1 diabetes and handling eye irritation—how would you respond to these cases?